Author:
Holstein Sarah A.,Avet-Loiseau Hervé,Hahn Theresa,Ho Christine M.,Lohr Jens G.,Munshi Nikhil C.,Paiva Bruno,Pasquini Marcelo C.,Tario Joseph D.,Usmani Saad Z.,Wallace Paul K.,Weisel Katja,McCarthy Philip L.
Funder
Blood and Marrow Transplant Clinical Trials Network
National Heart, Lung, and Blood Institute
National Cancer Institute
PRIMeR ancillary
Subject
Transplantation,Hematology
Reference56 articles.
1. Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes;Landgren;J Intern Med,2017
2. Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination As Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du Myélome
3. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma;Attal;N Engl J Med,2017
4. Final results of a phase II trial of extended treatment (tx) with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (KRd) plus autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM);Zimmerman;Blood (ASH Abstracts),2016
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献